Trial to Assess the Efficacy of F598 in Preventing an Experimental Urethral Infection With N. Gonorrhoeae in Healthy Males
Phase 2
Terminated
- Conditions
- Neisseria Gonorrhoeae
- Interventions
- Drug: 1 mg/kg single infusion of F598Drug: 3 mg/kg single infusion of F598Drug: 10 mg/kg single infusion of F598
- First Posted Date
- 2017-07-19
- Last Posted Date
- 2019-02-08
- Lead Sponsor
- Alopexx Pharmaceuticals, LLC
- Target Recruit Count
- 10
- Registration Number
- NCT03222401
- Locations
- 🇺🇸
University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, United States
© Copyright 2025. All Rights Reserved by MedPath